Evaluation of the EasySense System in Congestive Heart Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Across the globe, Congestive Heart Failure (CHF) continues to be the leading cause of mortality and hospitalizations in the 21st century. Despite advancements, prognosis often remains poor and mortality high. Congestive Heart Failure diagnoses are often characterized by frequent hospitalizations and re-admissions, and early detection of pulmonary edema, a chief characteristic of worsening heart failure, may have positive implications in patients' quality of life and frequency of hospitalizations. The EasySense device is a non-invasive device designed to measure lung fluid in patients with CHF. Similar to ultrasound technology, the device uses radiofrequency waves to assess fluid status. The device is placed on the bare skin of the chest and held in place for approximately 60 seconds to obtain a reading.
This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume. Seventy-five patients are sought for enrollment. Patients will be enrolled during their hospital stay, and will be asked to maintain daily EasySense measurements, in addition to other measurements, for thirty days post-discharge.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Current hospitalization for acute decompensated heart failure requiring IV diuretics or vasoactive drugs
- NYHA class II-IV
- Willing and able to participate in index and follow-up measurements
- Able to speak, read, and write in English
- Knows how to use a smartphone
- Preference for patients who undergo a right heart catheterization or continuous pulmonary artery monitoring upon admission or during hospitalization
Exclusion Criteria:
- Current or planned treatments with any inotropic agents or mechanical support (LVAD, intra-aortic balloon pump, invasive mechanically assisted ventilation) at time of enrollment
- Requiring demand pacing
- Prior heart transplant
- End-stage renal disease on hemodialysis
- Physical deformities in the thorax area that may prevent proper application of EasySense device, as assessed by investigator
- Sign of local rib cage or thoracic lesion or any illness which may be aggravated or cause significant discomfort from application of EasySense device, as assessed by investigator
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of volume status to EasySense measurements
Time Frame: 30 days
|
Patient volume status extracted from medical records will be compared to what the EasySense device measures.
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016H0069
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
NCT07356843RecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)
-
NCT03751904WithdrawnHeart Failure,Congestive
-
NCT01744210WithdrawnCongestive Heart Failure (CHF)
-
NCT00406575TerminatedCongestive Heart Failure (CHF)
-
NCT01414439UnknownCongestive Heart Failure (CHF)
-
NCT00528320Approved for marketing
-
NCT04180202TerminatedHeart Failure,Congestive
-
NCT03621436TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart Failure
-
NCT01502501WithdrawnNon-Ischemic Congestive Heart Failure
Clinical Trials on EasySense device
-
NCT07485582Not yet recruitingObstructive Sleep Apnea
-
NCT01914302Completed
-
NCT03716947UnknownDegenerative Disc Disease | Discogenic Low Back Pain
-
NCT05653583Not yet recruitingAtrial Fibrillation
-
NCT02326337Completed
-
NCT02940106Terminated
-
NCT05933616CompletedGlucose Metabolism Disorders | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease
-
NCT07548320CompletedTinnitus | Subjective Tinnitus
-
NCT05033600CompletedUnspecified Trauma- and Stressor-Related Disorder